Related by context. All words. (Click for frequent words.) 77 obatoclax 77 alvespimycin 76 PXD# 75 tanespimycin 75 HGS ETR1 75 CR# vcMMAE 75 Carfilzomib 75 INCB# [001] 74 OXi# 74 enzastaurin 74 Aplidin 74 HuMax EGFr 74 axitinib 74 CBLC# 74 anti leukemic 74 sapacitabine 73 XmAb# 73 RGB # 73 CA4P 73 Sym# 73 PRT# 73 BAY #-# 73 pertuzumab 73 PEG SN# 73 pomalidomide 73 IMA# 73 IMC A# 73 OncoVEX GM CSF 73 galiximab 73 oral prodrug 73 preclinically 72 elacytarabine 72 radiation sensitizer 72 sunitinib malate 72 AP# [003] 72 CCX# 72 Cloretazine ® 72 HGS ETR2 72 NEUGENE 72 MAGE A3 ASCI 72 ixabepilone 72 ENMD # 72 KRN# 72 HGS# 72 TELCYTA 72 AEG# 72 forodesine 72 MGCD# [001] 72 seliciclib 72 Virulizin ® 72 phase IIb clinical 72 Phase Ib study 71 Phase Ib 71 Tyrima 71 Blinatumomab 71 dacetuzumab 71 Panzem R NCD 71 Golimumab 71 IMGN# 71 OncoVEX 71 receptor tyrosine kinase inhibitor 71 Cloretazine 71 EOquin TM 71 Ceflatonin 71 elotuzumab 71 Perifosine 71 vemurafenib 71 adecatumumab 71 brentuximab vedotin SGN 71 BRAF inhibitor 71 oral ridaforolimus 71 atacicept 71 YONDELIS 71 Phase 1b trial 71 vidofludimus 71 OMP #M# 71 sorafenib Nexavar 71 proteasome inhibitor 71 ELACYT 71 Bezielle 71 voreloxin 71 Cloretazine R VNP#M 71 Xanafide 70 TACI Ig 70 phase Ib 70 liposomal formulation 70 Azedra 70 Symadex 70 eniluracil 70 HQK 70 trastuzumab DM1 T DM1 70 evaluating tivozanib 70 TOCOSOL Paclitaxel 70 oral antiviral 70 riociguat 70 PRTX 70 delafloxacin 70 PS# [001] 70 Traficet EN 70 PROSTVAC TM 70 neratinib 70 hematological cancers 70 Archexin 70 EndoTAG TM -1 70 Omacetaxine 70 vascular disrupting agent 70 Ophena TM 70 perifosine 70 Phase Ib II 70 ponatinib 70 relapsed multiple myeloma 70 INCB# [002] 70 Alocrest 70 HuMax CD4 70 SAR# [004] 70 ISIS # 70 novel anticancer 70 HuMax CD# 70 Aflibercept 70 HuLuc# 70 Bortezomib 70 romidepsin 70 IMC #B 70 mapatumumab 70 cediranib 70 MEK inhibitors 70 Panzem NCD 70 erlotinib Tarceva ® 70 Phase 2a trial 70 ongoing Phase 1b 70 Cloretazine R 70 lintuzumab 70 JAK2 inhibitor 69 Seliciclib 69 CYC# 69 BAL# [002] 69 LymphoStat B 69 Tesetaxel 69 DXL# 69 PEG Interferon lambda 69 PSMA ADC 69 VNP#M 69 sunitinib Sutent ® 69 CIMZIA ™ 69 huC# DM4 69 LY# [003] 69 ASONEP 69 tolerability profiles 69 TriRima 69 tezampanel 69 Onconase 69 GMX# 69 DAVANAT 69 HCD# [002] 69 otelixizumab 69 MyVax R 69 PSN# [002] 69 GRN# 69 orally bioavailable 69 APOPTONE 69 investigational humanized monoclonal antibody 69 CYT# potent vascular disrupting 69 talabostat 69 imatinib Gleevec ® 69 ruxolitinib 69 torezolid phosphate 69 teriflunomide 69 Enzastaurin 69 sorafenib Nexavar ® 69 phase IIa clinical 69 nab paclitaxel 69 fosbretabulin 69 AEGR 69 Targretin 69 Trastuzumab 69 JAK inhibitor 69 dasatinib Sprycel ® 69 phase IIb 69 radezolid 69 Pralatrexate 69 bevacizumab Avastin ® 69 ON #.Na 69 PDE4 inhibitor 69 orally administered inhibitor 69 MDV# 69 IAP inhibitor 69 deforolimus 69 depsipeptide 69 MEK inhibitor 69 Allovectin 7 ® 69 DermaVir Patch 69 favorable pharmacokinetic profile 68 Talabostat 68 Phase Ib clinical 68 viral kinetic 68 ZYBRESTAT 68 PNP inhibitor 68 HER2 positive metastatic breast 68 Pertuzumab 68 velafermin 68 Phase #b/#a 68 xenograft models 68 trabectedin 68 Amrubicin 68 Amigal 68 trastuzumab Herceptin 68 JAK1 68 dose escalation Phase 68 palifosfamide 68 pharmacodynamic properties 68 pralatrexate 68 pan HDAC inhibitor 68 vascular disrupting agents 68 NGX# 68 TOLAMBA 68 Neulasta ® 68 pharmacokinetic PK study 68 aleglitazar 68 INT# [002] 68 PF # [001] 68 Annamycin 68 leading oral taxane 68 BRIM2 68 CoFactor 68 farletuzumab 68 vosaroxin 68 Triolex 68 GFT# 68 GRN#L 68 DU #b 68 antitumor activity 68 NXL# 68 BiTE antibody 68 metaglidasen 68 SCH # 68 aflibercept VEGF Trap 68 mertansine 68 JAK2 inhibitors 68 Elotuzumab 68 Viramidine 68 NVA# 68 rNAPc2 68 Aplidin R 68 TRO# 68 entinostat 68 preclinical efficacy 68 sorafenib tablets 68 Chemophase 68 metastatic CRC 68 bendamustine 68 Nanobody ® 68 cilengitide 68 Phase #b/#a clinical 68 vorinostat 68 CYT# 68 OvaRex R 68 PANVAC VF 68 relapsed MM 68 tolerability profile 68 registrational 68 Zolinza 68 indibulin 68 epigenetic therapies 68 Panzem R 68 decitabine 68 dasatinib Sprycel 68 ocrelizumab 68 PI3K/Akt pathway inhibitor 68 XL# [003] 68 Phenoptin 68 lumiliximab 67 Tarvacin 67 AMN# [001] 67 Pazopanib 67 angiogenesis inhibitor 67 carfilzomib 67 ProSavin 67 thalidomide Thalomid 67 phase IIb trial 67 TTF Therapy 67 Romidepsin 67 microtubule targeting 67 talactoferrin 67 multitargeted 67 lenalidomide Revlimid R 67 subcutaneous formulation 67 tigecycline 67 olaparib 67 CIMZIA TM 67 eltrombopag 67 samalizumab 67 virus HCV protease inhibitor 67 ProLindac 67 Nanobody 67 antithrombotic 67 relapsed SCLC 67 crizotinib PF # 67 Phase #/#a 67 ridaforolimus 67 Urocidin 67 Doxil ® 67 investigational monoclonal antibody 67 pegylated interferons 67 Altastaph 67 PROCHYMAL 67 CLORETAZINE TM VNP#M 67 Tarceva TM 67 heavily pretreated patients 67 bortezomib Velcade 67 ISTODAX 67 posaconazole 67 trodusquemine 67 iclaprim 67 immunomodulatory 67 IAP inhibitors 67 dexpramipexole 67 bortezomib Velcade R 67 CRLX# 67 Mipomersen 67 phase IIb study 67 FOLOTYN ® 67 RDEA# 67 trastuzumab Herceptin ® 67 Triapine R 67 Quinamed 67 Valortim 67 relapsed refractory multiple myeloma 67 TMC# [002] 67 CCR5 antagonist 67 Allovectin 7 67 Vaxfectin TM 67 cMET 67 Aliskiren 67 XL# SAR# 67 ZOLINZA 67 belinostat 67 Phase IIIb clinical 67 Velcade bortezomib 67 nucleoside analog 67 CTAP# Capsules 67 Azixa 67 Tamibarotene 67 Thiovir 67 Dalbavancin 67 MKC# PP 67 PrevOnco 67 blinded randomized placebo controlled 67 docetaxel Taxotere R 67 GALNS 67 assessing T DM1 67 Sphingomab 67 sunitinib 67 oritavancin 67 Phase #/#a trial 67 lapatinib Tykerb 67 KNS # 67 #D#C# 67 MGd 67 Rigel R# 67 Pemetrexed 67 relapsed ovarian cancer 67 Onrigin 67 Voreloxin 67 RG# [001] 67 protein kinase inhibitor 67 oral picoplatin 67 retaspimycin 67 TYKERB 67 EGFR TKI 67 SNT MC# 67 Genasense ® 67 Dasatinib 67 imetelstat 67 glufosfamide 67 pharmacokinetic PK 67 celgosivir 67 novel VDA molecule 67 Sapacitabine 67 varespladib 67 Asentar 67 Tanespimycin 67 Phase 1b 67 ONCONASE 67 TPI ASM8 67 DACH platinum 67 custirsen 67 CINQUIL 67 registrational trial 67 CCR9 antagonist 67 refractory chronic lymphocytic 67 elvucitabine 67 tesetaxel 67 TG# [003] 67 CEQ# 67 ofatumumab 67 viral kinetics 67 Nexavar sorafenib 67 GAP #B# 67 cannabinor 67 TRIOLEX 67 rALLy trial 67 NEUMUNE 67 investigational HCV polymerase 66 Anthim 66 phase IIa 66 Civacir 66 BNC# 66 ZACTIMA 66 OncoVex 66 Vandetanib 66 Dapagliflozin 66 favorable tolerability 66 acyclovir Lauriad R 66 Multimeric 66 heavily pretreated 66 HSP# inhibitor 66 immunomodulator 66 anidulafungin 66 OvaRex ® MAb 66 EOquin 66 BRIM3 66 GW# [003] 66 zanolimumab 66 anti angiogenic agents 66 TREANDA 66 paclitaxel Taxol ® 66 Factor VIIa 66 Exelixis XL# 66 phase 2a 66 Deforolimus 66 aflibercept 66 OMNARIS HFA 66 midstage clinical 66 rBChE 66 docetaxel Taxotere ® 66 PDX pralatrexate 66 rilonacept 66 multi kinase inhibitor 66 Glufosfamide 66 Bicifadine 66 Panzem 66 combinability 66 elesclomol 66 rALLy clinical trial 66 amrubicin 66 tremelimumab 66 molecularly targeted 66 sargramostim 66 T DM1 66 BCX# 66 MEK inhibitor RDEA# 66 proteasome inhibitor bortezomib 66 HCV protease 66 temsirolimus 66 HCV SPRINT 66 ELND# 66 uric acid lowering 66 regorafenib 66 IRX 2 66 Daclizumab 66 CXB# 66 SUCCEED trial 66 Triapine 66 OMAPRO 66 targeting CD# 66 JAK inhibitors 66 evaluating Xcytrin 66 tipranavir 66 Vitaxin 66 Stedivaze 66 Phase IIa trial 66 alkylating agent 66 nilotinib 66 Tarvacin TM 66 lomitapide 66 PLX# 66 Tezampanel 66 NP2 Enkephalin 66 Phase 1a clinical 66 Randomized Phase 66 Gleevec resistant 66 QLT# 66 gefitinib Iressa 66 Phase 1b clinical trials 66 FOLOTYN 66 pharmacodynamic profile 66 solithromycin 66 recurrent glioblastoma multiforme 66 Zoraxel 66 mTOR inhibitors 66 reslizumab 66 unique alkylating agent 66 pharmacodynamic PD 66 PHX# 66 Exherin TM 66 vicriviroc 66 Arranon 66 Phase IIa trials 66 ISENTRESS 66 AeroLEF TM 66 triphendiol 66 AAG geldanamycin analog 66 ospemifene 66 XYOTAX TM 66 GV# [001] 66 LUX Lung 66 GRNVAC1 66 tezampanel NGX# 66 panitumumab Vectibix 66 Plicera 66 Fludara 66 Ceflatonin R 66 Atiprimod 66 GSK '# 66 Combo Stent 66 Excellarate 66 LAF# 66 HCV protease inhibitor 66 tipifarnib 66 OHR/AVR# 66 PCK# 66 ADVEXIN 66 systemically administered 66 chemopreventive agent 66 Capesaris 66 pradefovir 66 OMP #R# 66 MYCAMINE 66 alpha folate receptor 66 sorafenib Nexavar R 66 platinum refractory 66 TLR8 agonist 66 R#/MEM # 66 Copegus ribavirin 66 MYDICAR ® 66 Tavocept 66 BEXXAR 66 boosted protease inhibitor 66 subcutaneous PRO 66 Vilazodone 66 randomized Phase 2b 66 Reolysin 66 mycophenolate mofetil 66 class mGluR5 inhibitor 66 oral rivaroxaban 66 Telaprevir 66 clevidipine 66 APTIVUS 66 DDP# 66 GLYX 66 pharmacokinetic interactions 66 CD# antibody [001] 66 tocilizumab 66 zalutumumab 66 ADVANCE PD 66 MT# MEDI 66 ZD# [001] 66 vismodegib 66 Synavive 66 Elagolix 66 BRAF inhibitors 66 Dacogen injection 66 Intravenous CP 66 ATL# [001] 66 LT NS# 66 preclinical studies 66 LibiGel ® 66 Sudhir Agrawal D.Phil 66 SUTENT 66 safety tolerability pharmacokinetic 66 AZILECT R 66 multicenter Phase II 66 anticancer agent 66 Talactoferrin 66 APTIVUS r 66 TELINTRA 66 R roscovitine 66 ofatumumab HuMax CD# 66 rindopepimut 66 Hsp# inhibition 66 Exelixis compounds 66 antitumor 66 PKC# 66 oral FTY# 66 Aurora kinase 66 dosage regimens 66 bevacizumab Avastin 66 Taxotere ® 65 ESBA# 65 tesmilifene 65 MetMAb 65 TRV# [001] 65 XL# XL# XL# 65 AVE# 65 Darinaparsin 65 ImmunoVEX HSV2 65 G#DT 65 Telatinib 65 Genz # 65 BZL# 65 bosutinib 65 ToGA 65 BIBW 65 orally dosed 65 PREZISTA r 65 AMD# [003] 65 endothelin receptor antagonists 65 azacitidine 65 nitazoxanide 65 IDX# 65 dasatinib 65 EP #R 65 NEUGENE antisense 65 milatuzumab 65 JNJ Q2 65 UPLYSO 65 LEUKINE 65 Imprime PGG 65 Phase Ib clinical trials 65 erlotinib Tarceva 65 GLP toxicology studies 65 maximally tolerated dose 65 alfa 2a 65 Immunotherapeutic 65 MLN# 65 ritonavir boosted 65 dose escalation trial 65 Pimavanserin 65 antiangiogenic agents 65 Phase IIb trials 65 ASA# 65 randomized Phase IIb 65 MYDICAR 65 cariprazine 65 selective inhibition 65 ADP receptor antagonist 65 VEGF Trap 65 Allovectin 7 R 65 Phase 2b trial 65 metastatic RCC 65 immune modulatory 65 dose cohorts 65 Aurora Kinase 65 valopicitabine 65 Marqibo 65 cetuximab Erbitux 65 Amplimexon 65 ATL/TV# 65 adipiplon 65 gemcitabine Gemzar 65 ARIKACE 65 Targretin capsules 65 daptomycin 65 motesanib 65 TLK# 65 Phase IIa clinical 65 Fx #A 65 tyrosine kinase inhibitor 65 pazopanib 65 MAA submission 65 L BLP# 65 AQ4N 65 non nucleoside HCV 65 Hsp# inhibitor 65 LymphoStat B TM 65 ACZ# 65 systemic RNAi therapeutic 65 INC# 65 Laquinimod 65 therapeutic monoclonal antibody 65 DOXIL 65 eprotirome 65 HCV protease inhibitors 65 TKM ApoB 65 liposomal doxorubicin 65 Neuradiab 65 brivaracetam 65 selective androgen receptor modulator 65 Serdaxin 65 antiangiogenesis 65 dose escalation phase 65 Restanza 65 GAMMAGARD 65 TORISEL 65 selective modulator 65 refractory gout 65 anticancer activity 65 BAL# [001] 65 teduglutide 65 Phase 2b Clinical Trial 65 Aptivus 65 ENMD 65 CORT # 65 insulin sensitizing 65 histone deacetylase inhibitor 65 BrachySil 65 immunomodulating 65 docetaxel chemotherapy 65 AZILECT ® 65 Naproxcinod 65 Aclidinium 65 Phase IIb clinical trials 65 limiting toxicity 65 dose cohort 65 pegfilgrastim 65 PEG PAL 65 echinocandin 65 gemcitabine Gemzar ® 65 Vidofludimus 65 tivozanib 65 CRx 65 metastatic renal cell carcinoma 65 CDK inhibitor 65 DCCR 65 CD# monoclonal antibody 65 Metastatic Melanoma 65 VAPRISOL 65 pharmacodynamic effects 65 EZN 65 HRPC 65 picoplatin 65 nilotinib Tasigna ® 65 DCVax R 65 CGEN # 65 Icatibant 65 anticancer compound 65 AEZS 65 MGN# 65 SCCHN 65 atrasentan 65 XL# XL# XL# XL# 65 INTEGRILIN 65 Personalized Immunotherapy 65 HGS ETR1 mapatumumab 65 RAPTIVA 65 estramustine 65 Abiraterone acetate 65 mRCC 65 metastatic HRPC 65 cobiprostone 65 renin inhibitor 65 RhuDex ® 65 trastuzumab DM1 65 daclizumab 65 Arikace 65 Panitumumab 65 Phase 2a 65 paclitaxel Taxol 65 CG# [003] 65 MAXY G# 65 refractory CLL 65 Proxinium TM 65 Valortim R 65 Trofex 65 Boceprevir 65 Bafetinib 65 Alemtuzumab 65 huN# DM1 65 idarubicin 65 oral antidiabetic 65 Epratuzumab 65 Troxatyl 65 overlapping toxicities 65 FOLFOX6 chemotherapy regimen 65 Angiocept 65 pegylated liposomal doxorubicin 65 Bavituximab 65 Evoltra ® 65 potent antiviral 65 ALN TTR# 65 Erlotinib 65 BioVant 65 IL# PE#QQR 65 Cethrin 65 Interferon alpha 65 LymphoStat B belimumab 65 placebo controlled Phase 65 trastuzumab Herceptin R 65 Cannabinor 65 MET amplification 65 Phase IIB 65 BMS# 65 anti amnesic 65 urocortin 2 65 Radezolid 65 trabedersen 65 PROSTVAC VF 65 adecatumumab MT# 65 Zybrestat 65 Apoptone 65 CCR5 mAb 65 anticancer therapy 65 EGFR inhibitors 65 PARP inhibitor 65 PSN# [001] 65 DCVax ® 64 Rebif ® 64 gemcitabine cisplatin 64 tumor vascular disrupting 64 Leukine 64 NKTR 64 Cethromycin 64 personalized immunotherapy 64 MOZOBIL 64 ChronVac C ® 64 receptor inhibitor 64 Clolar ® 64 PLK1 SNALP 64 imatinib Gleevec 64 Ixempra 64 IIa trial 64 TBC# 64 Treanda 64 nucleoside analogues 64 Hsp# Inhibitor 64 HspE7 64 myeloproliferative disorders 64 selective kinase inhibitor 64 small molecule tyrosine 64 EndoTAGTM 1 64 gemcitabine carboplatin 64 ceftazidime 64 docetaxel Taxotere 64 drug conjugate 64 nilotinib Tasigna 64 anticancer therapies 64 S/GSK# 64 sipuleucel T 64 cetuximab Erbitux ® 64 ANG# 64 Gleevec imatinib mesylate 64 telaprevir VX 64 vandetanib 64 masitinib 64 Zerenex 64 AVN# [001] 64 GSK# [001] 64 BrachySil TM 64 Nexavar ® 64 Safinamide 64 Vidaza azacitidine 64 Actilon 64 ATL# [002] 64 Lorianne Masuoka MD 64 lenalidomide dexamethasone 64 refractory Hodgkin lymphoma 64 CANCIDAS 64 signal transduction inhibitor 64 TG# [001] 64 ularitide 64 Pivotal Phase III 64 SUTENT ® 64 tubulin inhibitor 64 pitavastatin 64 CCX# B 64 canakinumab 64 evaluating T DM1 64 Belimumab 64 tafamidis 64 AKT inhibitor 64 Bendamustine 64 Cloretazine VNP#M 64 ZK EPO 64 Vaxfectin 64 GLPG# 64 convenient dosing regimens 64 nucleoside reverse transcriptase inhibitor 64 dalbavancin 64 velafermin belinostat 64 polymerase inhibitor 64 Phase 1b clinical 64 darapladib 64 Vicinium TM 64 LHRH antagonists 64 initiate Phase 1b 64 Indibulin 64 antiviral efficacy 64 anti CD# antibodies 64 castration resistant prostate cancer 64 orBec 64 Anticalin ® 64 eosinophilic asthma 64 Pivotal Phase 64 abatacept Orencia 64 mTOR inhibitor 64 Telbivudine 64 Phase 2b study 64 platelet inhibitor 64 Opexa 64 vinca alkaloid 64 NOX E# 64 brostallicin 64 Guanilib 64 FTY# 64 metastatic castration resistant 64 efficacy tolerability 64 Sorafenib 64 tramiprosate Alzhemed TM 64 Advaxis Phase 64 tecarfarin 64 oral salmon calcitonin 64 demonstrated antitumor activity 64 ELND-#/AZD-# 64 #I TM# 64 recurrent glioblastoma 64 histone deacetylase HDAC inhibitor 64 alpha 2b 64 oral proteasome inhibitor 64 midstage trials 64 Litx 64 PRX # 64 polymerase inhibitors 64 oblimersen 64 BMS # 64 YONDELIS R 64 HDAC Inhibitor 64 generation Hsp# inhibitor 64 bortezomib 64 pharmacodynamic 64 eliglustat tartrate 64 novel tubulin binding 64 Hyphanox 64 Phase #b/#a trial 64 nonclinical studies 64 muraglitazar 64 EVIZON 64 EGS# 64 SinuNase 64 maribavir 64 Omacetaxine mepesuccinate 64 Elvitegravir 64 multicenter Phase 64 oral deforolimus 64 Hycamtin 64 Advexin 64 Twinrix 64 proteasome inhibitors 64 standard chemotherapy regimen 64 intranasal delivery 64 rhIL 7 64 SERMs 64 Omnitarg 64 Cotara 64 glatiramer acetate 64 protein kinase inhibitors 64 MERLIN TIMI 64 dose dose escalation 64 LEP ETU 64 PROSTVAC ® 64 Lacosamide 64 follicular NHL 64 Ophena 64 stated Michelle Berrey 64 Varespladib 64 ascending dose 64 Kahalalide F 64 isavuconazole 64 alpha 2a 64 anti VEGF 64 panitumumab 64 Fulvestrant 64 administered subcutaneously 64 Xeloda ® 64 cetuximab Erbitux R 64 corticosteroid dexamethasone 64 thymalfasin 64 Xelox 64 TroVax 64 apremilast 64 PEGylated 64 PEP# [003] 64 pharmacodynamics PD 64 Antiviral Activity 64 Fibrillex TM 64 integrase inhibitor 64 Phase IIb Trial 64 vivo efficacy 64 Phase 2b clinical 64 placebo controlled clinical 64 immunotherapeutic 64 hA# 64 IND submission 64 Ceplene/IL-2 64 Muraglitazar 64 Nicole Onetto MD 64 ILLUMINATE 64 Aurora kinase inhibitor 64 MabCampath 64 Lovaxin C 64 potent anticancer 64 Campath alemtuzumab 64 AMPK activators 64 Angiolix 64 antibody MT# 64 Pafuramidine 64 Squalamine 64 Hepatocellular Carcinoma HCC 64 darinaparsin 64 imatinib resistant